INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
J Clin Invest. 2024 Sep 17;134(22):e180738. doi: 10.1172/JCI180738.
Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy with limited therapeutic options. Single-cell analysis of clonal architecture demonstrates early clonal dominance with few residual WT hematopoietic stem cells. Circulating myeloid cells of the leukemic clone and the cytokines they produce generate a deleterious inflammatory climate. Our hypothesis is that therapeutic control of the inflammatory component in CMML could contribute to stepping down disease progression. The present study explored the contribution of immature granulocytes (iGRANs) to CMML progression. iGRANs were detected and quantified in the peripheral blood of patients by spectral and conventional flow cytometry. Their accumulation was a potent and independent poor prognostic factor. These cells belong to the leukemic clone and behaved as myeloid-derived suppressor cells. Bulk and single-cell RNA-Seq revealed a proinflammatory status of iGRAN that secreted multiple cytokines of which CXCL8 was at the highest level. This cytokine inhibited the proliferation of WT but not CMML hematopoietic stem and progenitor cells (HSPCs) in which CXCL8 receptors were downregulated. CXCL8 receptor inhibitors and CXCL8 blockade restored WT HSPC proliferation, suggesting that relieving CXCL8 selective pressure on WT HSPCs is a potential strategy to slow CMML progression and restore some healthy hematopoiesis.
慢性髓单核细胞白血病(CMML)是一种严重的髓系恶性肿瘤,治疗选择有限。克隆结构的单细胞分析表明早期克隆优势明显,WT 造血干细胞残留较少。白血病克隆的循环髓系细胞及其产生的细胞因子产生有害的炎症环境。我们的假设是,对 CMML 中炎症成分的治疗控制可能有助于减缓疾病进展。本研究探讨了不成熟粒细胞(iGRAN)对 CMML 进展的贡献。通过光谱和常规流式细胞术检测并定量了患者外周血中的 iGRAN。它们的积累是一个强有力的独立预后不良因素。这些细胞属于白血病克隆,并表现为髓系来源的抑制细胞。批量和单细胞 RNA-Seq 显示 iGRAN 具有促炎状态,分泌多种细胞因子,其中 CXCL8 水平最高。这种细胞因子抑制 WT 造血干细胞和祖细胞(HSPCs)的增殖,但不抑制 CMML HSPCs 的增殖,其中 CXCL8 受体下调。CXCL8 受体抑制剂和 CXCL8 阻断恢复了 WT HSPC 的增殖,这表明减轻 CXCL8 对 WT HSPC 的选择性压力是减缓 CMML 进展并恢复一些健康造血的潜在策略。